ArticleJournal of cancer survivorship : research and practice2026
Subsequent malignant neoplasm among cancer survivors in the United States.
Article in Journal of cancer survivorship : research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOne of the most significant events following a diagnosis of cancer is the diagnosis of subsequent malignant neoplasm (SMN). Estimates of the number and risk of more than one malignancy in this population are needed.
methodsUtilizing data from 1975 to 2021 from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program, estimates of the number, proportion, and standardized incidence ratios (SIRs) of survivors with SMN by age at diagnosis, time since diagnosis, and primary site were calculated.
resultsAs of January 1, 2022, the estimated number of cancer survivors in the US with one malignancy was 14,940,581, while 2,191,482 survivors had two malignancies. A smaller number of survivors (379,897) had three malignancies; 110,859 people had four or more malignancies. Compared to people who never had cancer, cancer survivors had an increased risk of SMN (SIR, 1.19; 95% CI, 1.19 to 1.19). Survivors diagnosed with the first malignancy before age 40 were at highest risk of SMN (SIR, 1.78; 95% CI, 1.76 to 1.81). Among all cancer survivors, 15.2% had an SMN, with the highest percentage of survivors with SMN observed among those with a history of melanoma, bladder cancer, or Hodgkin lymphoma.
conclusionMore than 2.5 million cancer survivors in the US have had two or more malignancies, representing 15% of the US cancer survivor population. The risk of SMN is notable for those diagnosed at a younger age and with certain types of first malignancies. IMPLICATIONS FOR CANCER SURVIVORS: About 15% of cancer survivors in the United States have had more than one malignancy.
Indexed as
Identifiers
42613555What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.